A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia The primary objective is to evaluate the efficacy of epratuzumab in WM as determined by the response rate for patients with partial or complete responses.

• Country None
• organs None
• Specialty None

A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia To determine if a subcutaneous dosing schedule of veltuzumab can be established in NHL or CLL paitent and to confirm safety and efficacy of veltuzumab that was previously established when administered...

• Country None
• organs None
• Specialty None

A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer To evaluate the feasibility, safety and tolerability of this treatment regimen, and to determine acceptable 90-Y dose and gemcitabine dosing for use with this approach.

• Country None
• organs None
• Specialty None

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.

• Country None
• organs None
• Specialty None

Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con placebo de Epratuzumab en pacientes con crisis agudas severas de Lupus Eritematoso Sistémico excluyendo los sistemas renal o neurológico El objetivo principal del estudio es demostrar que epratuzumab es eficaz para el tratamiento de la exacerbación aguda de lupus.

• Country None
• organs None
• Specialty None

Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose Gemcitabine Overall Survival (OS)

• Country None
• organs None
• Specialty None